Pulmonary *Mycobacterium abscessus* Infection with Reactive AA Amyloidosis: A Case Report and Brief Review of the Literature

Ryo Torii¹, Shingo Noguchi¹,², Ikuko Shimabukuro¹, Yuri Inokuchi¹, Akinari Tabaru¹, Chiharu Yoshii¹ and Kazuhiro Yatera²

Abstract:
We herein report a case involving a 64-year-old Japanese woman with a pulmonary *Mycobacterium abscessus* infection complicated by reactive AA amyloidosis, which, to our knowledge, has not been reported to date. The patient underwent gastrointestinal endoscopy for diarrhea during the treatment of pulmonary *M. abscessus* infection and was diagnosed with AA amyloidosis according to the histopathological findings from the endoscopic specimen. She died four months later. The prognosis of AA amyloidosis associated with pulmonary *M. abscessus* infection may be very poor, and physicians should pay attention to this rare condition when difficult-to-treat diarrhea occurs in patients with pulmonary *M. abscessus* infection.

Key words: *Mycobacterium abscessus*, non-tuberculous mycobacteria, reactive AA amyloidosis, poor prognosis

(Intern Med 58: 557-561, 2019)  
(DOI: 10.2169/internalmedicine.1263-18)

Introduction

*Mycobacterium abscessus* is globally localized in various environments and is a group IV member (rapidly growing mycobacteria; RGM) according to the Runyon classification (1). *M. abscessus* causes skin, soft tissue, and bone infection. Although pulmonary *M. abscessus* infection is a relatively rare respiratory infection (2), its incidence has been increasing in both immunocompetent and immunocompromised hosts (3-5). A large laboratory-based analysis in Japan demonstrated that pulmonary *M. abscessus* infection accounted for 2.6% of all pulmonary infections caused by nontuberculous mycobacteria (NTM), with an incidence rate similar to that of *M. kansasii* infection (2).

Amyloidosis is characterized by the deposition of amyloid protein in various systemic organs. AA amyloidosis is probably the most common type of amyloidosis worldwide, and it is often complicated by chronic systemic inflammation and infection (6). Various diseases, such as rheumatoid arthritis, ankylosing spondylitis, juvenile osteoporosis, Crohn’s disease, Castleman’s disease, neoplasms such as lymphoma and mesothelioma, and tuberculosis, may cause reactive AA amyloidosis (7). Among these diseases, tuberculosis has been the most common cause of reactive AA amyloidosis in the past; however, approximately 90% cases of reactive AA amyloidosis in recent years have been related to rheumatoid arthritis. Reactive AA amyloidosis associated with nontuberculous mycobacterial pulmonary infections is extremely rare and to our knowledge has never been reported in association with pulmonary *M. abscessus* infection.

We herein report a rare case involving a 64-year-old Japanese woman with pulmonary *M. abscessus* infection complicated by reactive AA amyloidosis and present a brief review of the relevant literature.

¹Department of Respiratory Medicine, Wakamatsu Hospital of the University of Occupational and Environmental Health, Japan, ²Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan and ³Department of Gastroenterology and Hepatology, Wakamatsu Hospital of the University of Occupational and Environmental Health, Japan

Received: March 26, 2018; Accepted: July 22, 2018; Advance Publication by J-STAGE: October 17, 2018
Correspondence to Dr. Shingo Noguchi, sn0920@med.uoeh-u.ac.jp
A 64-year-old Japanese woman visited a hospital with a low-grade fever and productive cough in April 2015. Chest computed tomography indicated nontuberculous mycobacterial pulmonary infection, although no NTM were cultured in the sputum. Two months later, treatment with clarithromycin (400 mg/day), rifampicin (300 mg/day), and ethambutol (750 mg/day) was initiated to treat with a radiological suspicion of NTM infection because she did not agree to a bronchoscopic examination; however, her symptoms did not improve after 2 months of treatment, which caused appetite loss and nausea. Therefore, her symptoms did not improve after 2 months of treatment, which caused appetite loss and nausea. Therefore, all three drugs were discontinued. 

She was referred to our hospital due to the development of a high-grade fever (38-39 °C) in September 2015. Chest computed tomography (CT) (Fig. 2A-C) demonstrated consolidations with cavitary lesions and bronchiectasis in the left upper lobe. Bronchoscopy was performed, but culture of bronchial washing specimens showed no mycobacteria. Treatment with erythromycin (EM) (200 mg/day) was initiated, which led to a slight improvement in the high-grade fever. However, she developed abdominal pain and diarrhea (5-6/day) in November 2015, and EM was discontinued. Her abdominal symptoms did not improve, and she was readmitted to our hospital for the evaluation of her abdominal symptoms in January 2016. 

On admission, a physical examination revealed the following: height, 155 cm; body weight, 29.0 kg; body mass index (BMI), 12.0 kg/m²; body temperature, 36.1 °C; heart rate, 109 beats/min; blood pressure, 107/63 mmHg; and oxygen saturation, 98% in room air. On auscultation, respiratory and cardiac sounds were normal, while hyper bowel sounds were audible. She did not have crimped edema. She also reported tenderness over the left lower abdomen. Laboratory tests (Table 1) revealed an elevated white blood cell count (19,200/μL) and serum C-reactive protein (6.7 mg/dL) level and hypalbuminemia (1.9 g/dL). Rheumatoid factor and antinuclear antibody were within normal limits, but the serum amyloid AA level was elevated (384 μg/mL; normal range, <10 μg/mL). In addition, there were no obvious abnormal urinary findings. A chest radiograph (Fig. 1) showed infiltrations in the left lung, and chest CT (Fig. 2D-F) demonstrated slightly worsening consolidation with cavitary lesions and bronchiectasis in the left upper lobe.

After admission, lower gastrointestinal endoscopy revealed red flare with hypervascularity of the mucosal membrane from the terminal ileum to the rectum (Fig. 3A). A histopathological examination of biopsied intestinal mucosa demonstrated positive Congo red staining, which was indicative of amyloid deposition, while immunostaining revealed anti-AA antibody-positive cells in the mucosa (Fig. 3B, C). These findings suggested AA amyloidosis. In addition, M. abscessus was cultured twice in sputum samples obtained at the time of admission. No other diseases that could cause reactive AA amyloidosis were evident, and the patient was diagnosed with pulmonary M. abscessus infection complicated by reactive AA amyloidosis.

Unfortunately, there were no treatment options for her condition, and she died four months after the diagnosis of reactive AA amyloidosis due to the aggravation of respiratory failure caused by the progression of M. abscessus infection.

### Discussion

Reactive AA amyloidosis associated with infection by NTM is extremely rare, and only six cases have been reported to date (6-11). To our knowledge, the present case is the first of reactive AA amyloidosis associated with M. abscessus infection.

Table 2 shows the characteristics of the reported patients, including our own (6-11). The previously reported cases were middle-aged (60-70 years old), with a male:female ratio of 3:4. Patients with NTM infection in Japan have been predominantly middle-aged women (2, 5), so there may be no marked sex- or age-related differences between patients with NTM infection with reactive AA amyloidosis and those with NTM infection without reactive AA amyloidosis, although the number of cases is few.

The major symptoms of patients with NTM infection complicated by reactive AA amyloidosis, including the present patient, were abdominal pain, stomachache, and diarrhea (Table 2). Cough, sputum, hemoptysis, and weight loss are common symptoms of NTM infection (5, 12, 13), although abdominal symptoms, such as diarrhea, are uncommon. In addition, intestinal NTM infection is generally quite rare, although Huh et al. reported that M. avium-intracellulare complex (MAC) was one of the common causes of intestinal infection in patients with acquired im-

---

**Figure 1.** Chest radiograph obtained on admission shows infiltration in the left lung.
Table 1. Findings of Peripheral Blood and Urine Analysis at Admission.

| <Blood cell counts> | <Blood chemistry> | <Serology> | <Urinalysis> |
|---------------------|-------------------|------------|--------------|
| WBC 19,200 /μL | TP 6.4 g/dL | CRP 6.7 mg/dL | Specific gravity 1.024 |
| Neut 87.1 % | Albumin 1.9 g/dL | RF 9.5 U/dL | pH 6.0 |
| Lymph 7.9 % | T-bil 0.7 mg/dL | Anti-nuclear antibody <40 | Urine sugar (+) mg/dL |
| Eo 0.2 % | AST 21 IU/L | T-bil 0.7 mg/dL | Urine protein 30 mg/dL |
| RBC 429×10⁴ /μL | ALT 14 IU/L | RF 9.5 U/dL | Urine protein (day) 0.1 g/day |
| Hb 10.8 g/dL | LDH 244 IU/L | FT4 1.65 ng/dL | |
| Ht 34.1 % | γ-GTP 22 IU/L | Specific gravity 1.024 | |
| Plt 59.4×10⁴ /μL | T-cho 164 mg/dL | pH 6.0 | |
| Cre 0.48 mg/dL | LDL-cho 90 mg/dL | Urine sugar (+) mg/dL | |
| Na 133 mEq/L | BUN 8 mg/dL | Urine protein 30 mg/dL | |
| K 4.6 mEq/L | Amyloid AA 384 μg/mL | Urine protein (day) 0.1 g/day | |
| Cl 94 mEq/L | |

WBC: white blood cell, RBC: red blood cell, Hb: hemoglobin, Ht: hematocrit, Plt: platelet, TP: total protein, T-bil: total bilirubin, AST: aspartate aminotransferase, ALT: alanine aminotransferase, LDH: lactate dehydrogenase, ALP: alkaline phosphatase, γ-GTP: gamma-glutamyl transpeptidase, BUN: blood urea nitrogen, Cre: creatinine, CRP: C-reactive protein, RF: rheumatoid factor, TSH: thyroid stimulating hormone, FT4: free thyroxine

 munodeficiency syndrome, and that intestinal MAC infection may lead to diarrhea (14, 15). The side effects of macrolide, a key drug for the treatment of NTM infection, also include abdominal symptoms, such as diarrhea. Thus, physicians should consider reactive AA amyloidosis associated with NTM infection as a differential diagnosis for diarrhea in patients with NTM infection. In addition, the digestive tract should be inspected before the discontinuation of macrolide in patients with refractory digestive symptoms.

Patients with reactive AA amyloidosis exhibit a relatively short mean survival time (24 months) (16), while patients with pulmonary *M. abscessus* infection also exhibit a poor prognosis and high mortality rate (15.0-16.7%) (1). The reported interval between the diagnosis of NTM and that of AA amyloidosis is approximately 5-8 years (6). Four of seven reported patients died within six months after the diagnosis of AA amyloidosis (Table 2). A low BMI, bilateral lung involvement, and the fibrocavitary type were predictors of a poor prognosis in patients with pulmonary *M. abscessus* infection (13). Reported factors for a poor prognosis in patients with AA amyloidosis include a decreased serum albumin level (<2.5 g/dL), end-stage renal failure at baseline, and an increased serum AA amyloid level during the follow-up period (16, 17), and Lachmann et al. reported that the se-
Controling the underlying diseases is the most effective treatment (20, 21), and whether or not treatment with EM is appropriate for M. abscessus infection remains controversial. Controlling the underlying diseases is the most effective treatment for achieving stabilization or even regression of amyloid deposition (22); therefore, treatment with clarithromycin, imipenem, and amikacin should probably have been administered to this patient. A further investigation is needed to determine the appropriate treatment regimen for patients with AA amyloidosis associated with pulmonary M. abscessus infection. In conclusion, we encountered a rare case of M. abscessus infection complicated by reactive AA amyloidosis. The findings from this case indicate that physicians should consider reactive AA amyloidosis associated with NTM infection when difficult-to-treat digestive symptoms, such as diarrhea, are observed in patients with NTM infection.

The authors state that they have no Conflict of Interest (COI).

References

1. Pasipanodya JG, Ogbonna D, Ferro BE, et al. Systematic review and meta-analyses of the effects of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence. Antimicrob Agents Chemother 61: 2017.
2. Morimoto K, Hasegawa N, Izumi K, et al. A laboratory-based analysis of nontuberculous mycobacterial lung disease in Japan from 2012 to 2013. Ann Am Thorac Soc 14: 49-56, 2017.
3. Lai CC, Hsueh PR. Diseases caused by nontuberculous mycobacteria in Asia. Future Microbiol 9: 93-106, 2014.
4. Benwill JL, Wallace RJ Jr. Mycobacterium abscessus: challenges in diagnosis and treatment. Curr Opin Infect Dis 27: 506-510, 2014.
5. Nagano H, Kinjo T, Nei Y, Yamashiro S, Fujita J, Kishaba T. Causative species of nontuberculous mycobacterial lung disease and comparative investigation on clinical features of Mycobacterium abscessus complex disease: a retrospective analysis for two major hospitals in a subtropical region of Japan. PLoS One 12: e0186826, 2017.

6. Tsuji K, Arai H, Furusu A, et al. A case of membranoproliferative glomerulonephritis and AA amyloidosis complicated with pulmonary nontuberculous mycobacterial infection. CEN Case Rep 4: 24-30, 2015.

7. Aharon A, Langevitz P, Maran R, Blank-Porat D, Shtrasburg S, Livneh A. Reactive amyloidosis in a patient with Mycobacterium simiae pulmonary infection. Respir Med 92: 123-124, 1998.

8. Zaizen Y, Arita K, Kawano H, et al. [A Case Report of AA Amyloidosis associated with Cystic Infection during the Course of Non-tuberculous Mycobacteriosis]. Respiration & Circulation 55: 237-241, 2007 (in Japanese).

9. Shinoura K, Kasamatsu N, Seto T, Yasui T, Nakamura A, Hashizume I. [A fatal case of pulmonary non-tuberculous mycobacteriosis with reactive AA amyloidosis]. Nihon Kokyuki Gakkai Zasshi 45: 636-642, 2007 (in Japanese).

10. Haga T, Kasamatsu N, Kobayashi T, Shibata M, Ogasawara T, Hashizume I. [A case of pulmonary nontuberculous Mycobacteriosis with reactive AA amyloidosis exacerbated in spite of various antimicrobial therapy]. The Japanese Journal of Chest Diseases 68: 245-251, 2009 (in Japanese).

11. Higuchi D, Nakamoto A. [A case of refractory diarrhea due to gastrointestinal AA amyloidosis occurred in nontuberculous mycobacteriosis with bronchiectasis]. The Journal of National Okinawa Hospital 34: 35-39, 2014 (in Japanese).

12. Huang HL, Cheng MH, Lu PL, et al. Epidemiology and predictors of NTM pulmonary infection in Taiwan - a retrospective, five-year multicenter study. Sci Rep 7: 16300, 2017.

13. Park J, Cho J, Lee CH, Han SK, Yim JJ. Progression and treatment outcomes of lung disease caused by Mycobacterium abscessus and Mycobacterium massiliense. Clin Infect Dis 63: 301-308, 2017.

14. Yamazaki R, Mori T, Nakazato T, et al. Non-tuberculous mycobacterial infection localized in small intestine developing after allogeneic bone marrow transplantation. Intern Med 49: 1191-1193, 2010.

15. Huh JG, Kim YS, Lee JS, et al. Mycobacterium ulcerans infection as a cause of chronic diarrhea in an AIDS patient: a case report. World J Gastroenterol 14: 808-811, 2008.

16. Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore) 70: 246-256, 1991.

17. Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356: 2361-2371, 2007.

18. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175: 367-416, 2007.

19. Komiyama K, Kurashima A, Ihi T, et al. Long-term, low-dose erythromycin monotherapy for Mycobacterium avium complex lung disease: a propensity score analysis. Int J Antimicrob Agents 44: 131-135, 2014.

20. Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 53: 1367-1376, 2009.

21. Renna M, Schaffner C, Brown K, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 121: 3554-3563, 2011.

22. Real de Asua D, Costa R, Galvan JM, Filigheddu MT, Trujillo D, Cadinanos J. Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol 6: 369-377, 2014.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).